Susan Wong
No más puestos en curso
Historial de carrera de Susan Wong
Antiguos cargos conocidos de Susan Wong.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Comptroller/Controller/Auditor | 01/01/2004 | 03/02/2014 |
Innoventry, Inc. | Comptroller/Controller/Auditor | 01/08/2000 | 01/10/2001 |
Ocular Sciences, Inc.
Ocular Sciences, Inc. Medical SpecialtiesHealth Technology Ocular Sciences, Inc. was manufacturer and marketer of contact lenses for annual and disposable replacement regimens. It used to manufacture soft contact lenses such as disposable toric, cosmetic, aspheric, multi-focal, sports and extended-wear lenses. Ocular sciences was marketing their products exclusively to eye care practitioners, both in private practice and retail chains. The company was founded in 1983 and was headquartered in Concord, CA. | Comptroller/Controller/Auditor | 01/09/1993 | 01/07/2000 |
Vanstar Corp.
Vanstar Corp. Miscellaneous Commercial ServicesCommercial Services Vanstar Corp. is a gold exploration company with properties located in northern Quebec. Vanstar also owns 100% of the Felix property under development in the Chicobi group and 100% of Amanda, a 7,679 ha property located on the Auclair formation with historic gold showings up to 12.1 g/t Au over 3 meters. The company is based in Canada. The American company owns a 25% interest in the Nelligan project, which won the "Discovery of the Year" award at the 2019 Quebec Mineral Exploration Association Xplor Gala. Vanstar was acquired by InaCom Corp. on February 17, 1999 for $436.07 million. | Comptroller/Controller/Auditor | 01/09/1989 | 01/01/1993 |
Formación de Susan Wong.
University of California, Berkeley | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 6 |
Operativa
Comptroller/Controller/Auditor | 4 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 3 |
Commercial Services | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 4 |
---|---|
Vanstar Corp.
Vanstar Corp. Miscellaneous Commercial ServicesCommercial Services Vanstar Corp. is a gold exploration company with properties located in northern Quebec. Vanstar also owns 100% of the Felix property under development in the Chicobi group and 100% of Amanda, a 7,679 ha property located on the Auclair formation with historic gold showings up to 12.1 g/t Au over 3 meters. The company is based in Canada. The American company owns a 25% interest in the Nelligan project, which won the "Discovery of the Year" award at the 2019 Quebec Mineral Exploration Association Xplor Gala. Vanstar was acquired by InaCom Corp. on February 17, 1999 for $436.07 million. | Commercial Services |
Ocular Sciences, Inc.
Ocular Sciences, Inc. Medical SpecialtiesHealth Technology Ocular Sciences, Inc. was manufacturer and marketer of contact lenses for annual and disposable replacement regimens. It used to manufacture soft contact lenses such as disposable toric, cosmetic, aspheric, multi-focal, sports and extended-wear lenses. Ocular sciences was marketing their products exclusively to eye care practitioners, both in private practice and retail chains. The company was founded in 1983 and was headquartered in Concord, CA. | Health Technology |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Innoventry, Inc. |
- Bolsa de valores
- Insiders
- Susan Wong
- Experiencia